Plain-English translation of NCT06491043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II clinical trial testing a new treatment called UMC119-06-05, which uses mesenchymal stem cells (special healing cells donated by healthy volunteers) delivered through an IV infusion. The trial aims to see whether this single infusion can help people with moderate to severe COPD improve their breathing and quality of life. Currently available COPD medications help manage symptoms, but they cannot reverse the gradual decline in lung function—this new treatment is being tested to see if it can do something different.
Most COPD treatments today only ease symptoms like shortness of breath but cannot stop the disease from getting progressively worse. Researchers believe this new stem cell treatment might actually help repair damaged lung tissue and reduce the inflammation that drives COPD, offering hope for better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you are selected, you will be randomly assigned to receive either a placebo (inactive saline solution), a lower dose of the stem cell treatment, or a higher dose of the stem cell treatment. You will receive a single intravenous infusion as an outpatient procedure. After that, the research team will monitor you over time with follow-up visits and tests to check your lung function, breathing symptoms, and overall safety—tracking how the treatment affects you in the long term.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
Taiwan